Applied Therapeutics (Applied Therapeutics) PEG Ratio : 0.00 (As of May. 26, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Applied Therapeutics PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Applied Therapeutics's PE Ratio without NRI is 0.00. Applied Therapeutics's 5-Year EBITDA growth rate is 12.80%. Therefore, Applied Therapeutics's PEG Ratio for today is 0.00.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

The historical rank and industry rank for Applied Therapeutics's PEG Ratio or its related term are showing as below:

APLT's PEG Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.49
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.

Applied Therapeutics PEG Ratio Historical Data

The historical data trend for Applied Therapeutics's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Applied Therapeutics PEG Ratio Chart

Applied Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

PEG Ratio

Get a 7-Day Free Trial

Applied Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
PEG Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Applied Therapeutics's PEG Ratio

For the Biotechnology subindustry, Applied Therapeutics's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Applied Therapeutics's PEG Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Applied Therapeutics's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Applied Therapeutics's PEG Ratio falls into.

Applied Therapeutics PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Applied Therapeutics's PEG Ratio for today is calculated as

PEG Ratio	=	PE Ratio without NRI	/	5-Year EBITDA Growth Rate*
	=		/	12.80
	=	0.00

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Applied Therapeutics (NAS:APLT) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.

Applied Therapeutics PEG Ratio Related Terms

Thank you for viewing the detailed overview of Applied Therapeutics's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Applied Therapeutics (Applied Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Applied Therapeutics Inc (NAS:APLT) » Definitions » PEG Ratio

Comparable Companies

Traded in Other Exchanges

2UV:Germany

Address

545 Fifth Avenue, Suite 1400, New York, NY, USA, 10017

Website

https://www.appliedtherapeutics.com

Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need.

Executives

Stacy J. Kanter	director	C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Shoshana Shendelman	director, 10 percent owner, officer: President and CEO	C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Adam Hansard	officer: Chief Commercial Officer	C/O APPLIED THERAPEUTICS, INC., 545 5TH AVENUE, SUITE 1400, NEW YORK NY 10017
Riccardo Perfetti	officer: Chief Medical Officer	C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Alexandria Real Estate Equities, Inc.	10 percent owner	26 NORTH EUCLID AVENUE, PASADENA CA 91101
Catherine Thorpe	officer: Chief Accounting Officer	545 FIFTH AVENUE, SUITE 1400, NEW YORK NY 10017
Chids Mahadevan	officer: Chief Accounting Officer	C/O APPLIED THERAPEUTICS, INC., 545 5TH AVENUE SUITE 1400, NEW YORK NY 10017
Steven A. Ortega	officer: Principal Accounting Officer	C/O APPLIED THERAPEUTICS, INC., 545 FIFTH AVENUE, SUITE 1400, NEW YORK NY 10017
Charles Silberstein	officer: Chief Financial Officer	C/O APPLIED THERAPEUTICS, INC., 545 5TH AVENUE SUITE 1400, NEW YORK NY 10017
Leslie D. Funtleyder	director	C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Joel S Marcus	director	C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Alexandria Equities No. 7, Llc	10 percent owner	26 NORTH EUCLID AVENUE, PASADENA CA 91101
Jay S Skyler	director	DANCE BIOPHARM INC., 150 NORTH HILL DRIVE, SUITE 24, BRISBANE CA 94005
Alexandria Venture Investments, Llc	10 percent owner	26 NORTH EUCLID AVENUE, PASADENA CA 91101
Teena Lerner	director	C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173